SomaLogic, Inc. (SLGC) News
Filter SLGC News Items
SLGC News Results
|Loading, please wait...|
SLGC News Highlights
- For SLGC, its 30 day story count is now at 4.
- Over the past 20 days, the trend for SLGC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AMP, BASE and RYAN are the most mentioned tickers in articles about SLGC.
Latest SLGC News From Around the Web
Below are the latest news stories about SOMALOGIC INC that investors may wish to consider to help them evaluate SLGC as an investment opportunity.
SomaLogic, Inc. (SLGC) Q4 2022 Earnings Call Transcript
SomaLogic, Inc. (SLGC)
Q4 2022 Earnings Conference Call
March 27, 2023, 04:30 PM ET
Marissa Bych - Investor Relations, Gilmartin Group LLC
Troy Cox - Chief Executive Officer
Shaun Blakeman - Chief Financial Officer
Adam Taich - EVP, Life Sciences Business Unit
Conference Call Participants
Dan Brennan - Cowen
Kyle Mikson - Canaccord Genuity
Welcome to SomaLogic's Fourth Quarter and Full Year 2022 Earnings Call. All participants are in a listen-only mode. We will take questions following prepared remarks.
I will now turn the call over to Marissa Bych of Gilmartin Group for introductory disclosu...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on!
SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management Evolution
Adam Taich, EVP Life Sciences, promoted to interim CEO with a focus on operational executionBoard transition adds industry veterans: Jason Ryan as Chairman; Tycho Peterson, Kathy Hibbs, and Tom Carey as Independent DirectorsFourth quarter 2022 revenue of $18.8 million; full year 2022 revenue of $97.7 million Full year 2023 revenue guidance of $80-84 million, reflecting 12-17% growth over 2022, excluding licensing revenue from New England Biolabs Substantial balance sheet provides flexibility wit
Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samples
BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world’s largest prospective studies. The SomaLogic team provided more than 28 million data points from the assay which will be combined with other available genetic, lifestyle, anthropometric and health outcome data to address a range of research questions. Th
SomaLogic to Announce Fourth Quarter and Full Year 2022 Financial Results
BOULDER, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, March 28, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the st
SomaLogic announces Certified Site expansion through world-class multiomics initiative with Group 42 Healthcare
BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), an artificial intelligence and cloud computing company. SomaLogic will become the sole provider of high-plex proteomics technology to G42. This initiative spans the United Arab Emirates (UAE) and Kingdom of Saud
SomaLogic Announces Preliminary Full Year 2022 Revenue and Provides Organizational and Strategic Updates
Presenting at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. Pacific TimeBOULDER, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that preliminary, unaudited revenue for the full year 2022 is expected to be at the high end of its guidance range of $93 to $98 million, reflecting approximately 20% year-over-year revenue growth. In addition, SomaLogic is pleased to announce several organizat
SomaLogic to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BOULDER, Colo., Dec. 29, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference. SomaLogic will present at the conference on Thursday, January 12, 2023 at 11:15 a.m. Pacific Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://investors.somalogic.com. About SomaLog
FonesLife offers the 7,000-plex SomaScan® Platform as Japan’s first SomaLogic™ Certified Site
TOKYO and BOULDER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomic technology, announced today that Tokyo-based FonesLife Corporation, will be the first SomaLogic™ Certified Site in Japan. The new site will offer the 7,000-plex SomaScan® Assay in their labs and provide SomaScan data to their customers. By becoming a SomaLogic Certified Site, FonesLife can now run assays on SomaLogic’s SomaScan Platform—the largest commercially available proteomic platform—and acce
Proteomics labs worldwide can now access SomaLogic’s industry-leading 7,000-plex SomaScan® Assay with the Certified Site program
BOULDER, Colo., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today the full-scale global launch of the SomaLogic™ Certified Site program, which will allow institutions around the world to run the 7,000-plex SomaScan® Assay in their own labs. By becoming a SomaLogic Certified Site, labs can run assays on SomaLogic’s SomaScan® Platform—the largest commercially available proteomics platform—and accelerate their own research and generate revenue as